Exicure Inc (XCUR)

$6.47 -0.31 (-4.57%)
Market Cap 42.84M
Revenue (ttm) 500,000.00
Net Income (ttm) -9.70M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -1,940.00%
Debt to Equity Ratio 0.00
Volume 34,100
Avg Vol 106,486
Day's Range N/A - N/A
Shares Out 6.32M
Stochastic %K 43%
Beta 3.57
Analysts Strong Buy
Price Target $2.00

Company Profile

Exicure, Inc. does not have significant operations. Previously, the company focused on developing of nucleic acid therapies targeting ribonucleic acid against validated targets. Exicure, Inc. was founded in 2011 and is headquartered in Redwood City, California.

Industry: Biotechnology
Sector: Healthcare
Phone: 847 673 1700
Address:
400 Seaport Court, Suite 102, Redwood City, United States
BullsEyePicks
BullsEyePicks Jul. 6 at 2:55 AM
Why everyone is bullish on PMAX , it meets the requirement for a massive squeeze up. Low float/high short interest/0 shares to borrow/Crypto sector/Dilution was terminated in May. Excitement on this is real! $SGLY $DGXX $XCUR $FLYE
0 · Reply
Stonkman88
Stonkman88 Jul. 3 at 3:21 PM
$XCUR wants to play with $RGC
0 · Reply
Stock_Catcher
Stock_Catcher Jul. 3 at 3:15 PM
$XCUR perking.
0 · Reply
SqueezeRib
SqueezeRib Jul. 3 at 3:01 PM
$XCUR 👀
0 · Reply
Stonkman88
Stonkman88 Jul. 3 at 2:58 PM
$RGC lessgoooo!! $XCUR symp!!
0 · Reply
Stonkman88
Stonkman88 Jul. 3 at 2:43 PM
$XCUR follow $RGC
0 · Reply
Stonkman88
Stonkman88 Jul. 3 at 2:39 PM
$XCUR
0 · Reply
HaltTradeAlert
HaltTradeAlert Jul. 3 at 2:14 PM
$XCUR Halt Time: 10:12:55 Issue Symbol: XCUR Reason Code: LUDP Members get this halt alert with no delay and with more info: last stock price, volume, shares outstanding, market cap, relative volume, and percentage change on the day. Also, halt alerts for pre-market hours and after market hours which is extremely important for Code T1 News Pending Alerts!! And free real time news catalyst alerts!
0 · Reply
11thestate
11thestate Jul. 2 at 10:55 AM
#Exicure has agreed to a $5.6M settlement with $XCUR investors over claims it overstated progress in preclinical research for a Friedreich’s ataxia treatment and hid key data issues. If you bought $XCUR between January 7, 2021, and December 10, 2021, you can file a claim for payment here: https://11th.com/cases/exicure-investor-settlement
0 · Reply
neosoul826
neosoul826 Jul. 1 at 5:50 PM
$XCUR I honestly don’t think so. Just a little experiment i ran today. I literally have gated the ask at 6.20 for the last 3hrs with 3.4k shares. Unless something huge happens from a PR perspective this isn’t coming close to 10 for a long time.
1 · Reply
Latest News on XCUR
Exicure, Inc. Reports First Quarter 2025 Financial Results

Jun 27, 2025, 4:01 PM EDT - 10 days ago

Exicure, Inc. Reports First Quarter 2025 Financial Results

Exicure, Inc. Received Nasdaq Delinquency Notice on Late Filing of its Form 10-Q

May 28, 2025, 4:58 PM EDT - 5 weeks ago

Exicure, Inc. Received Nasdaq Delinquency Notice on Late Filing of its Form 10-Q

Exicure Completes Patient Enrollment in Phase 2 Study of GPC-100 for Stem Cell Mobilization in Multiple Myeloma Patients Undergoing Autologous Transplant

May 5, 2025, 8:00 AM EDT - 2 months ago

Exicure Completes Patient Enrollment in Phase 2 Study of GPC-100 for Stem Cell Mobilization in Multiple Myeloma Patients Undergoing Autologous Transplant

Exicure, Inc. (Nasdaq: XCUR) Nears Completion of Phase 2 Study of GPC-100 in Multiple Myeloma

Apr 14, 2025, 6:11 PM EDT - 3 months ago

Exicure, Inc. (Nasdaq: XCUR) Nears Completion of Phase 2 Study of GPC-100 in Multiple Myeloma

Exicure, Inc. (Nasdaq: XCUR) Announces Their Next Step in Planning for a New Clinical Trial in Acute Myeloid Leukemia (AML)

Apr 11, 2025, 7:42 PM EDT - 3 months ago

Exicure, Inc. (Nasdaq: XCUR) Announces Their Next Step in Planning for a New Clinical Trial in Acute Myeloid Leukemia (AML)

Exicure, Inc. Reports Full Year 2024 Financial Results

Mar 18, 2025, 4:01 PM EDT - 3 months ago

Exicure, Inc. Reports Full Year 2024 Financial Results

Exicure, Inc. (Nasdaq: XCUR) Announces Issuance of New Patent in Australia

Mar 13, 2025, 4:08 PM EDT - 4 months ago

Exicure, Inc. (Nasdaq: XCUR) Announces Issuance of New Patent in Australia

CORRECTING and REPLACING Exicure, Inc. Announces Purchase Agreement with GPCR Therapeutics Inc.

Jan 23, 2025, 12:17 AM EST - 5 months ago

CORRECTING and REPLACING Exicure, Inc. Announces Purchase Agreement with GPCR Therapeutics Inc.

Exicure, Inc. Announces Purchase Agreement with GPCR Therapeutics Inc.

Jan 22, 2025, 4:01 PM EST - 5 months ago

Exicure, Inc. Announces Purchase Agreement with GPCR Therapeutics Inc.

Exicure, Inc. Partners with GPCR Therapeutics to Fuel New Growth in Biotech

Dec 26, 2024, 8:08 PM EST - 6 months ago

Exicure, Inc. Partners with GPCR Therapeutics to Fuel New Growth in Biotech

CORRECTING and REPLACING Exicure, Inc. Announces Shareholders Approve the $8.7 Million Equity Financing and Reports Executive Management and Board Changes

Dec 21, 2024, 1:48 PM EST - 7 months ago

CORRECTING and REPLACING Exicure, Inc. Announces Shareholders Approve the $8.7 Million Equity Financing and Reports Executive Management and Board Changes

Exicure, Inc. Announces Shareholders Approve the $8.7 Million Equity Financing and Reports Executive Management and Board Changes

Dec 20, 2024, 4:42 PM EST - 7 months ago

Exicure, Inc. Announces Shareholders Approve the $8.7 Million Equity Financing and Reports Executive Management and Board Changes

Exicure, Inc. Enters into Purchase Agreements for $1.3 Million and $8.7 Million Equity Financing and Reports Third Quarter 2024 Financial Results

Nov 14, 2024, 4:01 PM EST - 8 months ago

Exicure, Inc. Enters into Purchase Agreements for $1.3 Million and $8.7 Million Equity Financing and Reports Third Quarter 2024 Financial Results

Exicure, Inc. Receives Extension from Nasdaq Hearings Panel

Sep 18, 2024, 4:01 PM EDT - 10 months ago

Exicure, Inc. Receives Extension from Nasdaq Hearings Panel

Exicure, Inc. Announces 1-for-5 Reverse Stock Split

Aug 26, 2024, 9:08 AM EDT - 11 months ago

Exicure, Inc. Announces 1-for-5 Reverse Stock Split

Exicure, Inc. Announces Additional Adjournment of Special Meeting and Information for Reconvened Special Meeting

Aug 19, 2024, 10:31 AM EDT - 11 months ago

Exicure, Inc. Announces Additional Adjournment of Special Meeting and Information for Reconvened Special Meeting

Exicure, Inc. Announces Adjournment of Special Meeting and Information for Reconvened Special Meeting

Aug 15, 2024, 10:31 AM EDT - 11 months ago

Exicure, Inc. Announces Adjournment of Special Meeting and Information for Reconvened Special Meeting

Exicure, Inc. Reports Second Quarter 2024 Financial Results

Aug 13, 2024, 4:01 PM EDT - 11 months ago

Exicure, Inc. Reports Second Quarter 2024 Financial Results

Exicure, Inc. Recruits Head of Corporate Development and Bioinformatics

Aug 8, 2024, 4:27 PM EDT - 11 months ago

Exicure, Inc. Recruits Head of Corporate Development and Bioinformatics

Exicure, Inc. Receives Positive Listing Determination from Nasdaq

Aug 1, 2024, 4:01 PM EDT - 1 year ago

Exicure, Inc. Receives Positive Listing Determination from Nasdaq

Exicure, Inc. Reports First Quarter 2024 Financial Results

Jun 17, 2024, 4:01 PM EDT - 1 year ago

Exicure, Inc. Reports First Quarter 2024 Financial Results

Exicure, Inc. Reports Full Year 2023 Financial Results

Jun 6, 2024, 4:01 PM EDT - 1 year ago

Exicure, Inc. Reports Full Year 2023 Financial Results

Exicure, Inc. Received Nasdaq Notice of a Delisting Determination

May 23, 2024, 4:01 PM EDT - 1 year ago

Exicure, Inc. Received Nasdaq Notice of a Delisting Determination

Exicure, Inc. Reports Third Quarter 2023 Financial Results

May 16, 2024, 4:08 PM EDT - 1 year ago

Exicure, Inc. Reports Third Quarter 2023 Financial Results

Exicure, Inc. Received Nasdaq Delinquency Notice on Late Filing of its Form 10-K

Apr 22, 2024, 4:01 PM EDT - 1 year ago

Exicure, Inc. Received Nasdaq Delinquency Notice on Late Filing of its Form 10-K

Exicure, Inc. and Bluejay Therapeutics Inc. Enter into a Patent License Agreement to Develop Cavrotolimod for the Treatment of Hepatitis

Feb 5, 2024, 4:01 PM EST - 1 year ago

Exicure, Inc. and Bluejay Therapeutics Inc. Enter into a Patent License Agreement to Develop Cavrotolimod for the Treatment of Hepatitis

Exicure, Inc. Announces Appointment of New CEO and CFO and Changes to Board of Directors

Aug 23, 2023, 9:48 AM EDT - 2 years ago

Exicure, Inc. Announces Appointment of New CEO and CFO and Changes to Board of Directors

Exicure, Inc. Reports Second Quarter 2023 Financial Results and Provides Corporate Update

Aug 11, 2023, 4:01 PM EDT - 2 years ago

Exicure, Inc. Reports Second Quarter 2023 Financial Results and Provides Corporate Update

Exicure, Inc. Reports First Quarter 2023 Financial Results and Provides Corporate Update

Jul 14, 2023, 4:01 PM EDT - 2 years ago

Exicure, Inc. Reports First Quarter 2023 Financial Results and Provides Corporate Update

Exicure, Inc. Announces Support of CEO in its Ongoing Exploration of Strategic Alternatives

May 26, 2023, 4:01 PM EDT - 2 years ago

Exicure, Inc. Announces Support of CEO in its Ongoing Exploration of Strategic Alternatives

Exicure, Inc. Announces Investment in Korean SNS Platform Cyworld

May 4, 2023, 4:01 PM EDT - 2 years ago

Exicure, Inc. Announces Investment in Korean SNS Platform Cyworld

Exicure, Inc. Reports Full Year 2022 Financial Results and Provides Corporate Update

Mar 27, 2023, 4:01 PM EDT - 2 years ago

Exicure, Inc. Reports Full Year 2022 Financial Results and Provides Corporate Update

Exicure, Inc. Announces Closing of Private Placement Transaction with CBI USA, Inc. and Changes to the Board of Directors

Feb 24, 2023, 5:10 PM EST - 2 years ago

Exicure, Inc. Announces Closing of Private Placement Transaction with CBI USA, Inc. and Changes to the Board of Directors

Exicure, Inc. Announces Termination of AbbVie and Ipsen Collaboration Agreements

Dec 14, 2022, 5:00 AM EST - 2 years ago

Exicure, Inc. Announces Termination of AbbVie and Ipsen Collaboration Agreements

Exicure, Inc. Reports Third Quarter 2022 Financial Results and Provides Corporate Update

Nov 14, 2022, 4:01 PM EST - 2 years ago

Exicure, Inc. Reports Third Quarter 2022 Financial Results and Provides Corporate Update

Exicure, Inc. Enters Into Definitive Agreement With CBI USA, Inc. for $5.4 Million Equity Financing and Announces Implementation of Strategic Measure to Reduce Cash Burn and Prioritize Strategic Alternatives

Sep 26, 2022, 4:01 PM EDT - 3 years ago

Exicure, Inc. Enters Into Definitive Agreement With CBI USA, Inc. for $5.4 Million Equity Financing and Announces Implementation of Strategic Measure to Reduce Cash Burn and Prioritize Strategic Alternatives

Exicure Announces Presentation at Chardan's 6th Annual Genetic Medicines Conference

Sep 1, 2022, 7:00 AM EDT - 3 years ago

Exicure Announces Presentation at Chardan's 6th Annual Genetic Medicines Conference

Exicure, Inc. Reports Second Quarter 2022 Financial Results and Corporate Progress

Aug 15, 2022, 4:01 PM EDT - 3 years ago

Exicure, Inc. Reports Second Quarter 2022 Financial Results and Corporate Progress

Exicure, Inc. Regains Compliance with Nasdaq Minimum Bid Price Requirement

Jul 20, 2022, 4:01 PM EDT - 3 years ago

Exicure, Inc. Regains Compliance with Nasdaq Minimum Bid Price Requirement

Exicure, Inc. Announces Receipt of Nasdaq Notice of Non-compliance and Implementation of One-for-Thirty Reverse Stock Split

Jun 29, 2022, 12:00 PM EDT - 3 years ago

Exicure, Inc. Announces Receipt of Nasdaq Notice of Non-compliance and Implementation of One-for-Thirty Reverse Stock Split

Exicure, Inc. Announces Adjournment of Annual Meeting of Stockholders

May 27, 2022, 4:01 PM EDT - 3 years ago

Exicure, Inc. Announces Adjournment of Annual Meeting of Stockholders

Exicure Announces Presentation at 2022 H.C. Wainwright Global Life Sciences Conference

May 17, 2022, 7:00 AM EDT - 3 years ago

Exicure Announces Presentation at 2022 H.C. Wainwright Global Life Sciences Conference

Exicure, Inc. Reports First Quarter 2022 Financial Results and Corporate Progress

May 16, 2022, 4:01 PM EDT - 3 years ago

Exicure, Inc. Reports First Quarter 2022 Financial Results and Corporate Progress

Exicure Announces $5 Million Raise in Private Placement Transaction Priced at Market Premium

May 10, 2022, 7:21 PM EDT - 3 years ago

Exicure Announces $5 Million Raise in Private Placement Transaction Priced at Market Premium

Exicure to Present at Upcoming TIDES USA Oligonucleotide & Peptide Therapeutics Conference

May 9, 2022, 7:00 AM EDT - 3 years ago

Exicure to Present at Upcoming TIDES USA Oligonucleotide & Peptide Therapeutics Conference

Exicure Shares Plunge After Q4 Results Included A Going Concern Risk

Mar 28, 2022, 10:31 AM EDT - 3 years ago

Exicure Shares Plunge After Q4 Results Included A Going Concern Risk

Exicure, Inc. Reports Full Year 2021 Financial Results and Corporate Progress

Mar 25, 2022, 4:15 PM EDT - 3 years ago

Exicure, Inc. Reports Full Year 2021 Financial Results and Corporate Progress

Did You Acquire (XCUR) Before January 7, 2021? Should Management Be Held Accountable for Investors Losses?

Feb 17, 2022, 10:50 AM EST - 3 years ago

Did You Acquire (XCUR) Before January 7, 2021? Should Management Be Held Accountable for Investors Losses?

BullsEyePicks
BullsEyePicks Jul. 6 at 2:55 AM
Why everyone is bullish on PMAX , it meets the requirement for a massive squeeze up. Low float/high short interest/0 shares to borrow/Crypto sector/Dilution was terminated in May. Excitement on this is real! $SGLY $DGXX $XCUR $FLYE
0 · Reply
Stonkman88
Stonkman88 Jul. 3 at 3:21 PM
$XCUR wants to play with $RGC
0 · Reply
Stock_Catcher
Stock_Catcher Jul. 3 at 3:15 PM
$XCUR perking.
0 · Reply
SqueezeRib
SqueezeRib Jul. 3 at 3:01 PM
$XCUR 👀
0 · Reply
Stonkman88
Stonkman88 Jul. 3 at 2:58 PM
$RGC lessgoooo!! $XCUR symp!!
0 · Reply
Stonkman88
Stonkman88 Jul. 3 at 2:43 PM
$XCUR follow $RGC
0 · Reply
Stonkman88
Stonkman88 Jul. 3 at 2:39 PM
$XCUR
0 · Reply
HaltTradeAlert
HaltTradeAlert Jul. 3 at 2:14 PM
$XCUR Halt Time: 10:12:55 Issue Symbol: XCUR Reason Code: LUDP Members get this halt alert with no delay and with more info: last stock price, volume, shares outstanding, market cap, relative volume, and percentage change on the day. Also, halt alerts for pre-market hours and after market hours which is extremely important for Code T1 News Pending Alerts!! And free real time news catalyst alerts!
0 · Reply
11thestate
11thestate Jul. 2 at 10:55 AM
#Exicure has agreed to a $5.6M settlement with $XCUR investors over claims it overstated progress in preclinical research for a Friedreich’s ataxia treatment and hid key data issues. If you bought $XCUR between January 7, 2021, and December 10, 2021, you can file a claim for payment here: https://11th.com/cases/exicure-investor-settlement
0 · Reply
neosoul826
neosoul826 Jul. 1 at 5:50 PM
$XCUR I honestly don’t think so. Just a little experiment i ran today. I literally have gated the ask at 6.20 for the last 3hrs with 3.4k shares. Unless something huge happens from a PR perspective this isn’t coming close to 10 for a long time.
1 · Reply
budlite24
budlite24 Jul. 1 at 1:54 PM
$XCUR loading
0 · Reply
vitalyc87
vitalyc87 Jul. 1 at 11:21 AM
$XCUR should reach US$10 in the short term. Earnings are a strong catalyst.
0 · Reply
Candyman_Trader
Candyman_Trader Jun. 30 at 9:01 PM
$BMNR catch stocks like this one on my FREE YT LIVE stream starting at 6:45am everyday! Took my first position at $6.31... last out 42.90 woulda coulda shoulda done better but... we can't catch the whole move, just greateful it helped me recuperate my worst trade to date (bought $XCUR at 15.50 thinking it was breaking >16... -271$ in one swift gap down) GLTA still in BMNR... I'm being disciplined and waiting for morning link in bio
0 · Reply
Candyman_Trader
Candyman_Trader Jun. 30 at 8:22 PM
If it wasn't for a really dumb, but normal, mistake on $XCUR... this would of been my best day yet! Now feeling FOMO on $BMNR but... I will STAY DISCIPLINED and GRATEFUL for my day... red but very acceptable 😜 What a day?? GLTA
1 · Reply
_www_larval_com_
_www_larval_com_ Jun. 30 at 7:53 PM
$CIGL 8%[58%] $IPDN -6%[89%] $XCUR 6%[23%] $GNLN 6%[71%] $RCT 5%[-15%] most notable movement into the final minutes of trading.
0 · Reply
BillyRayValentine202
BillyRayValentine202 Jun. 30 at 7:51 PM
$XCUR
0 · Reply
BLACKFEATHER
BLACKFEATHER Jun. 30 at 6:46 PM
$XCUR totally dead
0 · Reply
neosoul826
neosoul826 Jun. 30 at 6:25 PM
$XCUR completely dead. Is it still trading?
0 · Reply
GAPMoney
GAPMoney Jun. 30 at 3:25 PM
$XCUR way oversold
0 · Reply
_www_larval_com_
_www_larval_com_ Jun. 30 at 3:08 PM
$XCUR has jumped 3% higher to 14% (~4Mv) a few minutes ago, follow for more volatility.
0 · Reply
topstockalerts
topstockalerts Jun. 30 at 2:30 PM
Top Gainers PT2 $VOR $XCUR $RITR $LIMN $CVKD
0 · Reply
PaulLaurent
PaulLaurent Jun. 30 at 2:04 PM
🚀📈 Top Gainers Update 💰🔥 $BMNR $ARTL $XCUR $KLTO $GNS
0 · Reply